Hand-foot syndrome

from Wikipedia, the free encyclopedia
Classification according to ICD-10
L27.1 Localized skin eruption from drugs or pharmaceuticals
ICD-10 online (WHO version 2019)

The hand-foot syndrome (HFS or palmar-plantar erythrodysesthesia , PPE) is an erythematous skin change on the palms of the hands and soles of the feet that is accompanied by painful swelling and reddening and that is an accompanying reaction to antineoplastic chemotherapy , as part of sickle cell anemia or when MEK inhibitors are taken can occur. Sensory disorders such as tingling or numbness are also observed. In severe cases, the skin can peel off. The extent varies from a painless swelling of the above-mentioned location (grade 1) to very painful blisters and skin detachments with corresponding functional restrictions (grade 3).

The pathogenesis is unclear; treatment is therefore limited to symptomatic measures such as the administration of painkillers , corticosteroids , vitamin B6 or creams containing 10% uridine.

Two red, swollen hands
Hand-foot syndrome

Cooling the skin areas should prevent the extent and severity of the symptoms.

Cytostatic drugs that can cause the hand-foot syndrome are, for example, capecitabine , cyclophosphamide , cytarabine , docetaxel , doxorubicin , 5-FU , oxaliplatin , paclitaxel , sorafenib and sunitinib .

MEK inhibitors are, for example Binimetinib , Cobimetinib, Selumetinib and trametinib .

Individual evidence

  1. ↑ Universimed Portal - View specialist topics. Retrieved July 29, 2019 .
  2. ↑ E. Nagore, A. Insa, O. Sanmartín: Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. In: American Journal of Clinical Dermatology 1 (4). 2000, pp. 225-234. (Review)
  3. ↑ Hendrik-Tobias Arkenau: Therapy Management: Capecitabine and the Hand-Foot Syndrome. 2006, accessed July 30, 2010 .
  4. ↑ Jürgen Barth: Uridine hand-foot ointment and uridine adhesive paste Antidota after accidental skin contamination with fluorouracil - a case report. (PDF; 96 kB) 2000, accessed on October 9, 2012 .
  5. ^ KL Molpus, LB Anderson, CL Craig, JG Puleo: The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. In: Gynecologic Oncology . 93 (2), 2004, pp. 513-516.

Web links